Influence of clinical and therapeutic indicators on the severity of neurocognitive deficits in patients with schizophrenia
https://doi.org/10.20538/1682-0363-2020-3-36-43
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Aim. To assess the association of clinical and therapeutic parameters with the severity of the neurocognitive deficits in patients with schizophrenia.
Materials and methods. We examined 118 patients with schizophrenia, aged 34 [29; 41] years, and with a disease duration of 10 [4; 16] years. 33 patients (28%) received conventional antipsychotic drugs (CAD), and 85 (72%) patients received atypical antipsychotic drugs (AAD). As concomitant therapy, 58 people (49.1%) took trihexyphenidyl, 60 people did not take it (50.9%). Assessment of cognitive functions was carried out for all patients using the Brief Assessment of Cognition in Schizophrenia (BACS), and clinical psychopathological symptomatology was evaluated using the Positive and Negative Syndrome Scale (PANSS). Statistical analysis of the data was performed using the Kruskal-Wallis test ANOVA with the multiple comparison procedure, the Pearson’s chi-squared test, and K-means cluster analysis.
Results. Neurocognitive deficits formed three clusters of disturbances that differ in clinical severity: 1) mild, 2) moderate, 3) severe. According to the subscale of positive PANSS symptoms, patients with mild neurocognitive deficits had a lower average total score compared to patients with severe neurocognitive deficits (p = 0.011), who, in turn, received significantly longer antipsychotic therapy compared with patients with moderate (p = 0.014) and mild (p = 0.01) neurocognitive deficits. Herewith, the duration of CAD treatment did not differ between clusters; consequently, the obtained results on antipsychotics as a whole were obtained due to AAD (p = 0.005 and p = 0.001, respectively). Trihexyphenidyl did not affect the severity of neurocognitive deficits.
Conclusion. The severity of positive symptoms of schizophrenia was lower in patients with mild neurocognitive deficits. The most pronounced neurocognitive deficits are observed in patients receiving AAD.
About the Authors
E. G. KornetovaRussian Federation
4, Aleutskaya Str., 634014, Tomsk, Russian Federation
A. A. Goncharova
Russian Federation
4, Aleutskaya Str., 634014, Tomsk, Russian Federation
E. G. Dmitrieva
Russian Federation
4, Aleutskaya Str., 634014, Tomsk, Russian Federation
A. A. Arzhanik
Russian Federation
7/9, Universitetskaya Emb., Saint-Petersburg, 199034, Russian Federation
A. N. Kornetov
Russian Federation
2, Moscow Trakt, 634055, Tomsk, Russian Federation
A. V. Semke
Russian Federation
4, Aleutskaya Str., 634014, Tomsk, Russian Federation
References
1. Servonnet A., Samaha A.N. Antipsychotic-evoked dopamine supersensitivity. Neuropharmacology. 2020; 163: 107630. https://doi.org/10.1016/j.neuropharm.2019.05.007.
2. Stępnicki P., Kondej M., Kaczor A. A. Current Concepts and Treatments of Schizophrenia. Molecules. 2018; 23(8): E2087. https://doi.org/10.3390/molecules23082087.
3. Ogino S., Miyamoto S., Tenjin T., Kitajima R., Ojima K., Miyake N. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2011; 35: 78-83. https://doi.org/10.1016/j.pnpbp.2010.08.030.
4. Keefe R.S.E., Harvey P.D. Cognitive impairment in schizophrenia. Handbook of Experimantal Pharmacology. 2012; Novel Antischizophrenia Tratments: 11-37.
5. Wojtalik J.A., Eack S.M., Pollock B.G., Keshavan M.S. Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia. Psychiatry Research. 2012; 204 (2-3): 61-67. https://doi.org/10.1016/j.pscychresns.2012.04.014.
6. Desmarais J.E., Beauclair L., Annable L., Belanger M.C., Kolivakis T.T., Margolese H.C. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. Therapeutic Advances in Psychopharmacology. 2014; 4(6): 257-67. https://doi.org/10.1177/2045125314553611.
7. Jann M.W. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy. 2004; 24: 1759-83. https://doi.org/10.1592/phco.24.17.1759.52346.
8. Tandon R., Greden J.F., Silk K.R. Treatment of negative schizophrenic symptoms with trihexyphenidyl. Journal of Clinical Psychopharmacology. 1988; 8(3): 212-215. https://doi.org/10.1097/00004714-198806000-00012.
9. Baitz H.A., Thornton A.E., Procyshyn R.M., Smith G.N., MacEwan G.W., Kopala L.C., Barr A.M., Lang D.J., Honer W.G. Antipsychotic medications: linking receptor antagonism to neuropsychological functioning in first episode psychosis. Journal of the International Neuropsychological Society. 2012; 18: 717-727. https://doi.org/10.1017/S1355617712000343.
10. Eum S., Hill S.K., Rubin L.H., Carnahan R.M., Reilly J.L., Ivleva E.I., Keedy S.K., Tamminga C.A., Pearlson G.D., Clementz B.A., Gershon E.S., Keshavan M.S., Keefe R.S.E., Sweeney J.A., Bishop J.R. Cognitive burden of anticholinergic medications in psychotic disorders. Schizophrenia Research. 2017; 190: 129-135. https://doi.org/10.1016/j.schres.2017.03.034.
11. World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders - Diagnostic Criteria for Research. Geneva: WHO, 1993.
12. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biological Psychiatry. 2010; 67: 255-262. https://doi.org/10.1016/j.biopsych.2009.08.040.
13. Keefe R.S., Harvey P.D., Goldberg T.E. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research. 2008; 102 (1-3): 108-115. https://doi.org/10.1016/j.schres.2008.03.024.
14. Sarkisyan G.R., Gurovich I.Ya., Keefe R.S. Normative data for the Russian population and standardization of the brief assessment of cognition in schizophrenia (BACS) scale. Social and Clinical Psychiatry. 2010; 20 (3): 13-19 (in Russ.).
15. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987; 13 (2): 261-76. https://doi.org/10.1093/schbul/13.2.261.
16. Mosolov S.N. Psychometric rating scales of symptoms of schizophrenia and concept of cognitive and negative disorders. Moscow, 2001: 238 (in Russ.).
17. Mel’nikov M.Y., Bezmaternykh D.D., Petrovskiy E.D., Kozlova L.I., Shtark M.B., Savelov A.A., Shubina O.S., Natarova K.A. The response time to emotional stimuli (including facial expressions photos) during the fMRI scanning in affective disorders: mild and moderate depression and dysthymic disorder. Bulletin of Siberian Medicine. 2018; 17 (1): 130-138 (in Russ.). https://doi.org/10.20538/1682-0363-2018-1-130-138.
18. Polyakov V.M., Rychkova L.V., Belogorova T.A., Mikhnovich V.I., Bugun O.V., Berdina O.N., Prokhorova Z.V., Teterina T.A., Lebedeva L.N., Lebedeva L.I. Influence of L-tryptophan use on the dynamics of cognitive functions in the complex therapy of delayed psycho-speech development in children. Bulletin of Siberian Medicine. 2018; 17 (2): 71-79 (in Russ.). https://doi.org/10.20538/1682-0363-2018-2-71-79.
19. Lebedeva E.V., Gorokhov A.S., Schastnyy E.D., Repin A.N., Simutkin G.G., Shishneva E.V., Perchatkin V.A., Surovtseva A.K., Winter S., Karpov R.S., Bokhan N.A. Time course of cognitive dysfunction and biochemical marker of CNS lesions S100ß in coronary artery bypass graft. Bulletin of Siberian Medicine. 2018; 17 (4): 72-84 (in Russ.). https://doi.org/10.20538/1682-0363-2018-4-72-84.
20. Brébion G., Bressan R.A., Amador X., Malaspina D., Gorman J.M. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychological Medicine. 2004; 34(2): 369-374. https://doi.org/10.1017/s0033291703008900.
21. Ostanko V.L., Kalacheva T.P., Kalyuzhina E.V., Livshits I.K., Shalovay A.A., Chernogoryuk G.E., Bespalova I.D., Yunusov R.S., Lukashova L.V., Pomogaeva A.P., Teplyakov A.T., Kalyuzhin V.V. Biological markers in risk stratification and progression of cardiovascular disease: present and future. Bulletin of Siberian Medicine. 2018; 17 (4): 264-280 (in Russ.). https://doi.org/10.20538/1682-0363-2018-4-264-280.
22. Lupu A.M., Clinebell K., Gannon J.M., Ellison J.C., Chengappa K.N.R. Reducing anticholinergic medication burden in patients with psychotic or bipolar disorders. The Journal of Clinical Psychiatry. 2017; 78(9): e1270-e1275. https://doi.org/10.4088/JCP.16m11269.
23. Harvey P.D. Cognitive and functional effects of atypical antipsychotic medications. The Journal of Clinical Psychiatry. 2006; 67: e13. https://doi.org/10.4088/JCP.1006e13.
24. Mishara A.L., Goldberg T.E. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biological Psychiatry. 2004; 55: 1013-1022. https://doi.org/10.1016/j.biopsych.2004.01.027.
25. Mariyan K. Topolov M.K., Getova D.P. Cognitive impairment in schizophrenia, neurotransmitters and the new atypical antipsychotic aripiprazole. Folia Medica. 2016; 58(1): 12-18. https://doi.org/10.1515/folmed-2016-0002.
26. Nielsen R.E., Levander S., Kjaersdam T.G., Jensen S.O., Ostergaard Ch.T., Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia - A meta-analysis of randomized clinical trials. Acta Psychiatrica Scandinavica. 2015; 131: 185. https://doi.org/96. 10.1111/acps.12374.
27. Keefe R.S.E., Harvey P.D., Khan A., Saoud J.B., Staner C., Davidson M., Luthringer R. Cognitive Effects of MIN-101 in Patients with Schizophrenia and Negative Symptoms: Results from a Randomized Controlled Trial. Journal of Clinical Psychiatry. 2018; 79 (3). https://doi.org/10.4088/JCP.17m11753.
28. Shmukler A.B., Semenkova E.A. Age-related characteristics of neurocognitive deficit at early stages of schizophrenia and schizophrenia spectrum disorders. Social and Clinical Psychiatry. 2010; 23 (4): 19-23 (in Russ.).
Review
For citations:
Kornetova E.G., Goncharova A.A., Dmitrieva E.G., Arzhanik A.A., Kornetov A.N., Semke A.V. Influence of clinical and therapeutic indicators on the severity of neurocognitive deficits in patients with schizophrenia. Bulletin of Siberian Medicine. 2020;19(3):36-43. https://doi.org/10.20538/1682-0363-2020-3-36-43
ISSN 1819-3684 (Online)